They can now choose among 4 novel second-generation hormone therapies (the androgen receptor pathway inhibitors [ARPIs] abiraterone, enzalutamide, apalutamide, and darolutamide), 2 chemotherapy ...
In mid-2024, the Company initiated once daily dosing of ORIC-944 in combination with 240 mg QD apalutamide or with 600 mg BID darolutamide, as part of the ongoing Phase 1b trial in patients with ...
Announces encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with apalutamide in patients with mCRPC. Entered into clinical tr ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback